Introduction {#s1}
============

Bladder cancer (BC) is the most common malignancy of the urinary tract. According to the American Cancer Society, 79,030 new cases of bladder cancer and 18,540 deaths were estimated to occur in the United States alone in 2017 ([@bib79]). Predominantly of urothelial histology, invasive BC arises from non-invasive papillary or flat precursors, and many BC patients suffer multiple relapses prior to progression, providing ample lead-time for early detection and treatment prior to metastasis ([@bib61]).

Although most urothelial carcinomas arise in the bladder, 5--10% originate in the renal pelvis and/or ureter ([@bib69]; [@bib81]). The annual incidence of these upper tract urothelial carcinomas (UTUC) in Western countries is 1--2 cases per 100,000 ([@bib69]; [@bib81]), but the disease occurs at a much higher rate in populations exposed to aristolochic acid (AA) ([@bib9]; [@bib26]; [@bib45]; [@bib84]). AA is a carcinogenic and nephrotoxic nitrophenanthrene carboxylic acid produced by *Aristolochia* plants ([@bib58]). An etiological link between AA exposure and UTUC has been established in several populations ([@bib26]; [@bib25]; [@bib37]; [@bib58]). The profound public health threat posed by the medicinal use of *Aristolochia* herbs is illustrated in Taiwan, which has the highest incidence of UTUC in the world ([@bib9]; [@bib95]). In recent years, more than one-third of the adult population in Taiwan has been prescribed herbal remedies containing AA ([@bib32]), resulting in an unusually high (37%) proportion of UTUC cases relative to urothelial cancers worldwide ([@bib84]).

Tumors of the upper and lower urinary tracts differ in important ways, including etiology, but they have many common features ([@bib24]), such as the somatic alterations that drive their growth ([@bib46]). High rates of activating mutations in the upstream promoter of the *TERT* gene are found in the majority of urothelial neoplasms of both upper and lower tracts ([@bib34]; [@bib40]; [@bib74]; [@bib96]). *TERT* promoter mutations predominantly affect two hot spots, g.1295228 C \> T and g.1295250 C \> T. These mutations generate CCGGAA/T or GGAA/T motifs that alter the binding site for ETS transcription factors and subsequently stimulate increased *TERT* promoter activity ([@bib31]; [@bib34]). *TERT* promoter mutations occur in up to 80% of invasive urothelial carcinomas of the bladder and in several of their histologic variants ([@bib1]; [@bib12]; [@bib40]; [@bib43]; [@bib63]). Moreover, *TERT* promoter mutations occur in 60--80% of BC precursors, including papillary urothelial neoplasms of low malignant potential ([@bib68]), non-invasive low-grade papillary urothelial carcinoma, non-invasive high-grade papillary urothelial carcinoma and 'flat' carcinoma in situ (CIS), as well as in urinary cells from a subset of these patients ([@bib43]). *TERT* promoter mutations have thus been established as a common genetic alteration in urothelial neoplasms ([@bib11]; [@bib40]; [@bib43]; [@bib96]).

Other important oncogene-activating mutations include those in *FGFR3*, *RAS* and *PIK3CA* genes, which occur in a high fraction of non-muscle invasive bladder cancers ([@bib35]; [@bib60]). In muscle-invasive bladder cancers, mutations in the *TP53, CDKN2A, MLL* and *ERBB2* genes are also frequently found ([@bib7]; [@bib50]; [@bib54]; [@bib60]; [@bib72]; [@bib71]; [@bib70]; [@bib93]). Mutations in these genes are also present in UTUC ([@bib29]; [@bib46]; [@bib57]; [@bib76]).

Urine cytology is a non-invasive method for the detection of BC. Although it has value for the detection of high-grade BC, the test is unable to detect the vast majority of low-grade tumors ([@bib51]; [@bib62]; [@bib98]). Urine cytology also fails to detect the majority of UTUCs ([@bib2]). These facts, together with the high cost and invasive nature of repeated endoscopy and follow-up biopsy procedures, have led to many attempts to develop alternative minimally invasive methods to detect urothelial cancers. Strategies to identify BC include urine- or serum-based genetic and protein assays for screening and surveillance ([@bib1]; [@bib3]; [@bib18]; [@bib20]; [@bib22]; [@bib36]; [@bib38]; [@bib43]; [@bib44]; [@bib55]; [@bib66]; [@bib73]; [@bib75]; [@bib80]; [@bib88]; [@bib94]). Currently available U.S. Food and Drug Administration (FDA) approved assays for BC diagnosis include the ImmunoCyt test (Scimedx Corp), the nuclear matrix protein 22 (NMP22) immunoassay test (Matritech), and multitarget FISH (UroVysion) ([@bib20]; [@bib38]; [@bib44]; [@bib55]; [@bib73]; [@bib80]; [@bib94]). Sensitivities between 62% and 69% and specificities between 79% and 89% have been reported for some of these tests. However, due to assay performance inconsistencies, cost or requirements for technical expertise, integration of such assays into routine clinical practice has not yet occurred. Furthermore, none of the FDA-approved BC assays have yet been validated for clinical use in detection of UTUC. Therefore, a non-invasive test that predicts which patients are most likely to develop urothelial cancer could be medically and economically important.

As urothelial cells from the upper and lower urinary tracts are in direct contact with urine, we hypothesized that genetic analyses of exfoliated urinary cells could be used to detect neoplasia in these organs in a non-invasive fashion. The current study assesses the performance of a massively parallel sequencing-based assay, termed UroSEEK, for the detection of BC and UTUC through the genetic analysis of urinary cell DNA. UroSEEK has three components: detection of intragenic mutations in regions of ten genes (*FGFR3, TP53, CDKN2A, ERBB2, HRAS, KRAS, PIK3CA, MET, VHL and MLL*) frequently mutated in urothelial tumors ([@bib7]; [@bib29]; [@bib46]; [@bib50]; [@bib54]; [@bib57]; [@bib60]; [@bib72]; [@bib71]; [@bib70]; [@bib76]; [@bib93]); detection of mutations in the *TERT* promoter ([@bib34]; [@bib40]; [@bib74]; [@bib96]); and detection of aneuploidy ([@bib42]; [@bib41]). The exons and specific genes chosen for inclusion in UroSEEK were chosen on the basis of BC mutations recorded in the COSMIC database ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). Selected amplicons from VHL and MET were also included in the hope that renal cell carcinomas might also shed cells into urine, although urine samples from patients with these cancers were not included in our study.

UroSEEK was applied to three independent cohorts of patients. The first (called the BC early detection cohort) exhibited microscopic hematuria or dysuria and supplied urine samples prior to any surgical procedures. A small fraction (4% to 5%) of patients with microscopic hematuria later develops urothelial malignancy ([@bib92]; [@bib53]), so the decision as to which patients should undergo cystoscopy is often difficult. The second cohort (called the UTUC cohort) consisted of Taiwanese patients with UTUC who supplied a urine sample prior to nephroureterectomy. Such patients might benefit from a non-invasive test that could be used to screen individuals at increased risk for UTUC, such as those exposed to herbal remedies containing the carcinogen AA. The third cohort (called the BC surveillance cohort) included patients who had already been diagnosed with BC and were therefore at high risk for recurrence ([@bib92]). Because urine cytology is relatively insensitive for the detection of recurrence, cystoscopies are performed as often as every three months in such patients in the U.S. In fact, the cost of managing these patients is in aggregate higher than the cost of managing any other type of cancer, amounting to 3 billion dollars annually ([@bib59]).

Results {#s2}
=======

A schematic of the approach used in this study is provided in [Figure 1](#fig1){ref-type="fig"}. A flow diagram indicating the number of patients evaluated in this study and the major results are presented in [Figure 2](#fig2){ref-type="fig"}.

![Schematic of the approach used to evaluate urinary cells in this study.\
UroSEEK assay is designed to detect urothelial neoplasms that are in direct contact with urine (**A**) of variable pathologic stages originating in upper urinary tract (**B**) or bladder (**C**).](elife-32143-fig1){#fig1}

![Flow diagram indicating the number of patients in the three cohorts evaluated in this study and summarizing the salient findings.\
Cytology was performed on only a subset of the patients (see main text).](elife-32143-fig2){#fig2}

BC early detection cohort {#s2-1}
-------------------------

### Cohort characteristics {#s2-1-1}

A total of 570 patients were included in the early detection cohort, each with one urine sample analyzed. 90% of the patients had hematuria, 3% had lower urinary tract symptoms (LUTS), and 9% had other indications suggesting they were at risk for BC. The median age of the participants was 58 years (range 5 to 89 years; [Table 1a](#table1){ref-type="table"}). As expected from prior studies of patients at risk for BC, 70% of the patients were male ([@bib79]; [@bib92]). Patients (*n* = 175; 31%) developed BC after a median follow-up period of 18 months (range 0 to 40 months). For each patient who developed BC, we selected two other patients who presented with similar symptoms but did not develop BC during the follow-up period. By design, the fraction of cases in this cohort developing BC was higher than the fraction (5%) of patients with similar presentations who would have developed BC in standard clinical practice. The characteristics of the tumors developing in the 570 patients are summarized in [Table 1a](#table1){ref-type="table"} and detailed in [Supplementary file 2](#supp2){ref-type="supplementary-material"}.
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###### Demographic, clinical and genetic features of the early detection cohort.

  Gender                                                                               n     \%     Ten-gene multiplex positive   TERT positive   Aneuploidy positive   UroSEEK positive   Cytology positive\*   Uroseek or cytology positive\*
  ------------------------------------------------------------------------------------ ----- ------ ----------------------------- --------------- --------------------- ------------------ --------------------- --------------------------------
  Table 1a. Demographic, clinical and genetic features of the early detection cohort                                                                                                                             
  Males without recurrence                                                             172   59%    3 (2%)                        10 (6%)         2 (1%)                13 (8%)            0 (0%)                13 (8%)
  Males with recurrence                                                                32    11%    26 (81%)                      21 (66%)        19 (59%)              29 (91%)           16 (50%)              30 (94%)
  Females without recurrence                                                           81    28%    2 (2%)                        2 (2%)          1 (1%)                5 (6%)             0 (0%)                5 (6%)
  Females with recurrence                                                              9     3%     4 (44%)                       4 (44%)         3 (33%)               6 (67%)            1 (11%)               6 (67%)
  *Indication*                                                                                                                                                                                                   
  Hematuria without recurrence                                                         346   61%    6 (2%)                        15 (4%)         5 (1%)                22 (6%)            0 (0%)                17 (5%)
  Hematuria with recurrence                                                            163   29%    108 (66%)                     90 (55%)        76 (47%)              134 (82%)          18 (11%)              32 (2%)
  LUTS without recurrence                                                              11    2%     0 (0%)                        2 (18%)         0 (0%)                2 (18%)            0 (0%)                2 (18%)
  LUTS with recurrence                                                                 3     1%     2 (67%)                       1 (33%)         0 (0%)                2 (67%)            1 (33%)               2 (67%)
  Other without recurrence                                                             38    7%     1 (3%)                        0 (0%)          1 (3%)                2 (5%)             0 (0%)                2 (5%)
  Other with recurrence                                                                9     2%     9 (100%)                      8 (89%)         5 (56%)               9 (100%)           2 (22%)               9 (100%)
  *Detected Tumor Diagnosis*                                                                                                                                                                                     
  PUNLMP                                                                               2     1%     0 (0%)                        1 (50%)         0 (0%)                1 (50%)            0 (0%)                0 (0%)
  CIS                                                                                  7     5%     4 (57%)                       4 (57%)         1 (14%)               6 (86%)            3 (43%)               6 (86%)
  LGTCC                                                                                31    21%    15 (48%)                      18 (58%)        9 (29%)               22 (71%)           0 (0%)                4 (13%)
  HGTCC                                                                                49    33%    34 (69%)                      28 (57%)        26 (53%)              40 (82%)           4 (8%)                11 (22%)
  INTCC                                                                                61    41%    48 (79%)                      36 (59%)        35 (57%)              57 (93%)           9 (15%)               16 (26%)
  *Cytology diagnosis\**                                                                                                                                                                                         
  Positive                                                                             21    6%     16 (76%)                      12 (57%)        16 (76%)              20 (95%)           N/A                   N/A
  Atypical                                                                             105   30%    21 (20%)                      21 (30%)        12 (11%)              30 (29%)           N/A                   N/A
  Negative                                                                             221   64%    4 (2%)                        9 (4%)          1 (0.4%)              12 (5%)            N/A                   N/A
  Table 1b. Demographic, clinical and genetic features of the Surveillance cohort.                                                                                                                               
  *Males without recurrence*                                                           59    30%    3 (5%)                        8 (14%)         3 (5%)                10 (17%)           0 (0%)                8 (14%)
  *Males with recurrence*                                                              90    45%    45 (50%)                      53 (59%)        20 (22%)              59 (66%)           20 (22%)              53 (59%)
  *Females without recurrence*                                                         17    9%     5 (29%)                       3 (18%)         0 (0%)                6 (35%)            0 (0%)                6 (35%)
  *Females with recurrence*                                                            33    17%    15 (45%)                      19 (58%)        11 (33%)              33 (100%)          6 (18%)               19 (58%)
  *Original Tumor Diagnosis*                                                                                                                                                                                     
  *PUNLMP*                                                                             12    4%     5 (42%)                       2 (17%)         1 (8%)                6 (50%)            0 (0%)                2 (17%)
  *CIS*                                                                                25    8%     11 (44%)                      13 (52%)        6 (24%)               14 (56%)           5 (20%)               10 (40%)
  *LGTCC*                                                                              107   35%    27 (25%)                      34 (32%)        8 (7%)                41 (38%)           0 (0%)                59 (55%)
  *HGTCC*                                                                              62    20%    22 (36%)                      24 (39%)        10 (16%)              30 (49%)           4 (7%)                16 (26%)
  *INTCC*                                                                              104   34%    39 (38%)                      47 (45%)        29 (28%)              54 (52%)           20 (19%)              34 (33%)
  *Original Tumor Stage*                                                                                                                                                                                         
  *pTis*                                                                               25    8%     11 (44%)                      13 (52%)        6 (24%)               14 (56%)           5 (20%)               10 (40%)
  *pTa*                                                                                181   58%    54 (30%)                      60 (33%)        19 (19%)              77 (43%)           4 (2%)                77 (43%)
  *pT1*                                                                                71    23%    28 (39%)                      35 (49%)        22 (31%)              39 (55%)           14 (20%)              23 (32%)
  *pT2*                                                                                23    7%     9 (9%)                        9 (39%)         7 (30%)               12 (52%)           5 (22%)               10 (43%)
  *pT3*                                                                                9     3%     1 (11%)                       2 (22%)         0                     2 (22%)            1 (11%)               1 (11%)
  *pT4*                                                                                1     0.3%   1 (100%)                      1 (100%)        0                     1 (100%)           N/A                   N/A
  *Routine cytology diagnosis\**                                                                                                                                                                                 
  *Positive*                                                                           30    15%    21 (21%)                      25 (83%)        20 (67%)              27 (90%)           N/A                   N/A
  *Atypical*                                                                           95    48%    38 (40%)                      43 (45%)        18 (19%)              50 (53%)           N/A                   N/A
  *Negative*                                                                           71    36%    12 (17%)                      13 (18%)        3 (4%)                19 (27%)           N/A                   N/A

\*Cytology was available on only a subset of cases.

N/A Not Available.

### Genetic analysis {#s2-1-2}

We performed three separate tests for genetic abnormalities that might be found in urinary cells derived from BC ([Figure 1](#fig1){ref-type="fig"}). First, we evaluated mutations in selected regions of ten genes that have been shown to be frequently altered in urothelial tumors ([Figure 3](#fig3){ref-type="fig"} and [Supplementary file 3](#supp3){ref-type="supplementary-material"}). For this purpose, we designed a specific set of primers that allowed us to detect mutations in as few as 0.03% of urinary cells ([Supplementary file 4](#supp4){ref-type="supplementary-material"}). The capacity to detect such low-mutant fractions was a result of the incorporation of molecular barcodes in each of the primers, thereby substantially reducing the artifacts associated with massively parallel sequencing ([@bib41]). Second, we evaluated *TERT* promoter mutations. A singleplex PCR was used for this analysis because the unusually high GC-content of the *TERT* promoter precluded its inclusion in the multiplex PCR design. Third, we evaluated the extent of aneuploidy using a technique in which a single PCR is used to co-amplify \~38,000 members of a subfamily of long interspersed nucleotide element-1 retrotransposons (L1 retrotransposons, also called LINEs). L1 retrotransposons, like other human repeats, have spread throughout the genome via retrotransposition and are found on all 39 non-acrocentric autosomal arms ([@bib42]).

![Fraction of mutations found in the ten-gene panel in 231 urinary cell samples assessed in the BC early detection cohort, 56 urinary cell samples assessed in the UTUC cohort, and 132 urinary cell samples assessed in the BC surveillance cohort.](elife-32143-fig3){#fig3}

The multiplex assay detected mutations in 68% of the 175 urinary cell samples from the individuals who developed BC during the course of this study (95% CI, 61% to 75%) ([Table 1a](#table1){ref-type="table"} and [Supplementary file 5](#supp5){ref-type="supplementary-material"}). A total of 246 mutations were detected in eight of the ten target genes ([Figure 3](#fig3){ref-type="fig"} and [Supplementary file 5](#supp5){ref-type="supplementary-material"}). The median mutant allele frequency (MAF) in the urinary cells with detectable mutations was 8% (8.14%. The most commonly altered genes were *TP53* (45% of the total mutations) and *FGFR3* (20% of the total mutations; [Figure 3](#fig3){ref-type="fig"}). The distribution of mutant genes was roughly consistent with expectations based on previous exome-wide sequencing studies of BCs ([@bib7]). At the thresholds used, 1.7% of the 395 patients in the early detection cohort who did not develop BC during the course of the study had a detectable mutation in any of the ten genes. At the same thresholds, none of the 188 urinary cell samples from healthy individuals had a mutation in any of the ten genes assayed (100% specificity, 95% CI, 98% to 100%).

Mutations in the *TERT* promoter were detected in 57% of the 175 urinary cell samples from the patients who developed cancer during the study interval (95% CI, 49% to 64%; [Table 1a](#table1){ref-type="table"} and [Supplementary file 6](#supp6){ref-type="supplementary-material"}). The median *TERT* MAF in the urinary cells was 6% (5.76%). Mutations were detected in three positions; 98% of the mutations were at TERT:g.1295228 (79%) and TERT:g.1295250 (19%), which are 66 and 88 bp upstream of the transcription start site, respectively. The remaining 2% of mutations were found at TERT:g.1295242. The first two of these positions have been previously shown to be critical for the appropriate transcriptional regulation of *TERT*. In particular, the mutant alleles recruit the GABPA/B1 transcription factor, resulting in the H3K4me2/3 mark of active chromatin and reversing the epigenetic silencing present in normal cells ([@bib83]). Of the 395 patients in this cohort who did not develop BC during the course of the study, only 4% had a detectable mutation in the *TERT* promoter. Finally, only one of the 188 urinary samples from healthy individuals harbored a *TERT* promoter mutation.

Aneuploidy was detected in 46% (95% CI, 39% to 54%) of the 175 urinary cell samples from the patients who developed BC during the course of the study ([Table 1a](#table1){ref-type="table"} and [Supplementary file 7](#supp7){ref-type="supplementary-material"}). The most commonly altered chromosome arms were 5q, 8q, and 9p. These three chromosome arms harbor well-known oncogenes and tumor suppressor genes that have been shown to undergo copy number alterations in many cancers, including BC ([@bib87]). Aneuploidy was detected in 1.5% of the urinary cell samples from the 395 patients who did not develop BC during the course of the study, but it was not detected in any of the 188 urinary samples from healthy individuals.

### Comparison with primary tumors {#s2-1-3}

DNAs from resected or biopsied tumor samples from 102 of the patients enrolled in the BC early detection cohort were available for comparison and were examined with the same three assays used to probe the urinary cell samples. In 91 (89%) of these 102 cancers, at least one mutation in the eleven genes studied was present (in the 10-gene panel or the *TERT* promoter). Moreover, at least one of the mutations identified in the urine samples from these 102 patients was also identified in 83% of the corresponding primary BC samples ([Supplementary files 5](#supp5){ref-type="supplementary-material"} and [6](#supp6){ref-type="supplementary-material"}).

Analysis of these tumors also shed light on the basis for 'false negatives,' the urine samples with no detectable mutations from patients who ultimately developed BC. We attributed false negatives to the possibility that the corresponding BC either did not harbor a mutation in any of these 11 genes or the fraction of neoplastic cells in the urine sample was insufficient to allow detection with the assays used. We identified a mutation in at least one of the 11 genes in 62% of the primary tumors from patients with false negative urine tests ([Supplementary file 3](#supp3){ref-type="supplementary-material"} and [8](#supp8){ref-type="supplementary-material"}). We concluded that 62% of the 29 false negative tests were due to insufficient cancer cells in the urine while the remaining 38% were due to the absence of any of the queried mutations in the primary tumor tissue.

### UroSEEK: biomarkers in combination {#s2-1-4}

The ten-gene multiplex assay, the *TERT* singleplex assay, and the aneuploidy assays yielded 68%, 57%, and 46% sensitivities, respectively, when used separately ([Table 1a](#table1){ref-type="table"} and [Supplementary files 5](#supp5){ref-type="supplementary-material"}, [6,](#supp6){ref-type="supplementary-material"} and [7](#supp7){ref-type="supplementary-material"}). Sensitivity was increased when the three assays were performed on each urine cell sample. In samples without *TERT* promoter mutations (*n* = 45), mutations in one of the other ten genes were detected ([Figure 4](#fig4){ref-type="fig"} and [Supplementary file 5](#supp5){ref-type="supplementary-material"}). Conversely, 35 samples negative for mutations in the multiplex assay were detected by virtue of *TERT* promoter mutations ([Figure 4](#fig4){ref-type="fig"} and [Supplementary file 6](#supp6){ref-type="supplementary-material"}). Finally, ten of the urinary cell samples without any detectable mutations in the 11 genes were positive for aneuploidy ([Figure 4](#fig4){ref-type="fig"} and [Supplementary file 7](#supp7){ref-type="supplementary-material"}). Thus, when the three assays were used together (test termed 'UroSEEK'), and a positive result in any one of the assays was sufficient to score a sample as positive, the sensitivity rose to 83% (95% CI, 76% to 88%). Only one of the 188 samples from healthy individuals was scored positive by UroSEEK (specificity 99.5%, CI 97% to 100%). Twenty-six (6.5%) of the 395 patients in the BC early detection cohort who did not develop BC during the course of the study scored positive by the UroSEEK test (specificity 93%, CI 91% to 96%). On average, UroSEEK positivity preceded the diagnosis of BC by 2.3 months, and in eight cases, by \>one year ([Figure 5](#fig5){ref-type="fig"} and [Supplementary file 2](#supp2){ref-type="supplementary-material"}).

![Venn diagram showing the distribution of positive results for each of the three UroSEEK assays for the (A) BC early detection (B) UTUC and (C) BC surveillance cohorts.\
URO = Ten gene panel, *TERT* = *TERT* promoter region, ANEU = Aneuploidy test.](elife-32143-fig4){#fig4}

![Bar graphs of the lead time between a positive UroSEEK test and the detection of disease at the clinical level in the (**A**) BC early detection and (**B**) BC surveillance cohorts.](elife-32143-fig5){#fig5}

### UroSEEK plus cytology {#s2-1-5}

As both cytology and UroSEEK are non-invasive tests and can be performed on the same urine sample, we assessed their performance in combination. Cytology was available for 347 patients in the BC early detection cohort ([Table 1a](#table1){ref-type="table"} and [Supplementary file 2](#supp2){ref-type="supplementary-material"}). Among the 40 patients who developed biopsy-proven cancer in this cohort, cytology was positive in 17 cases (43% sensitivity), and UroSEEK was positive in 100% of these cancer patients. UroSEEK was also positive in 95% of 23 cancer patients whose urines were negative by cytology. Thus, in combination, UroSEEK plus cytology achieved 95% (95% CI, 83% to 99%) sensitivity, a 12% increase over UroSEEK and a 52% increase over cytology. Finally, none of the 299 patients who did not develop cancer over the course of the study were positive by cytology (100% specificity), but 20 (6.6%) were positive by UroSEEK, giving the combination of UroSEEK and cytology a specificity of 93% (95% CI, 90% to 96%).

UTUC cohort {#s2-2}
-----------

### Cohort characteristics {#s2-2-1}

The gender distribution of this cohort, 32 females and 24 males, is atypical of UTUC patients in Western countries where males predominate ([@bib77]), but is consistent with earlier epidemiologic studies of Taiwanese individuals with known exposures to AA (summary in [Table 2](#table2){ref-type="table"}; individual data in [Supplementary file 9](#supp9){ref-type="supplementary-material"})([@bib9]). Tobacco use was reported by 18% in this cohort and were all males. Based on estimated glomerular filtration rate (eGFR) values, renal function was unimpaired (chronic kidney disease (CKD) stage 0--2) in 45% of the subjects, while mild-to-moderate renal disease (CKD stage 3) or severe disease (CKD stages 4--5) was noted for 43% and 12% of the cohort, respectively ([Table 2](#table2){ref-type="table"}). Tumors were confined to a single site along the upper urinary tract in the majority of cases (38% renal pelvis; 39% ureter), while multifocal tumors affecting both renal pelvis and ureter occurred in 23% of the patients. Synchronous bladder cancer (diagnosed within 3 months prior to nephroureterectomy) was present in 38% of patients. Tumors were classified as high grade in 89% of the cases, with the majority categorized as muscle-invasive (T2-T4, 66%; [Table 2](#table2){ref-type="table"}).

10.7554/eLife.32143.008

###### Demographic, clinical and genetic features of the UTUC cohort stratified by UroSEEK results.

                                              N    \%     Ten-gene multiplex positive   TERT positive   Aneuploidy positive   UroSEEK positive
  ------------------------------------------- ---- ------ ----------------------------- --------------- --------------------- ------------------
  **All subjects**                            56   100%   64%                           29%             39%                   75%
  **Gender**                                                                                                                  
   Males                                      24   43%    71%                           33%             54%                   83%
   Females                                    32   57%    59%                           25%             28%                   69%
  **CKD stage**                                                                                                               
   0--2                                       25   45%    68%                           36%             44%                   76%
   3A                                         14   25%    50%                           21%             43%                   71%
   3B                                         10   18%    80%                           20%             40%                   80%
   4                                          4    7%     25%                           50%             0%                    50%
   5                                          3    5%     100%                          0%              33%                   100%
  **Tumor grade**                                                                                                             
   Low                                        6    11%    67%                           50%             17%                   67%
   High                                       50   89%    64%                           26%             42%                   76%
  **Tumor stage**                                                                                                             
   Ta                                         11   20%    73%                           55%             45%                   82%
   T1                                         8    14%    50%                           0%              38%                   75%
   T2                                         10   18%    80%                           20%             10%                   80%
   T3                                         24   43%    67%                           33%             54%                   79%
   T4                                         3    5%     0%                            0%              0%                    0%
  **Upper urinary tract tumor site**                                                                                          
   Lower ureter                               17   30%    76%                           18%             35%                   76%
   Upper ureter                               1    2%     100%                          0%              0%                    100%
   Ureterovesical junction                    2    4%     0%                            0%              0%                    0%
   Lower ureter and upper ureter              2    4%     100%                          50%             50%                   100%
   Renal pelvis                               21   38%    57%                           38%             38%                   76%
   Renal pelvis and lower ureter              4    7%     75%                           25%             50%                   100%
   Renal pelvis and upper ureter              5    9%     40%                           40%             60%                   60%
   Renal pelvis, lower ureter, upper ureter   4    7%     75%                           25%             50%                   75%
  **Synchronous bladder cancer**                                                                                              
   Present                                    21   38%    52%                           29%             33%                   62%
   Absent                                     35   63%    71%                           29%             43%                   83%
  **UTUC risk factors**                                                                                                       
   Aristolactam-DNA adducts present           54   96%    65%                           30%             39%                   74%
   Smoking history                            10   18%    70%                           30%             60%                   70%
   CKD, chronic kidney disease.                                                                                               

### Genetic analysis {#s2-2-2}

The multiplex assay detected at least one mutation in 36 of the 56 urinary cell samples from UTUC patients (64%, 95% CI, 51% to 76%; [Table 2](#table2){ref-type="table"} and [Supplementary file 10](#supp10){ref-type="supplementary-material"}). A total of 57 mutations were detected in nine of the ten target genes ([Figure 3](#fig3){ref-type="fig"}). The median MAF in the urinary cells was 5.6% and ranged from 0.3% to 80%. The most commonly altered genes were *TP53* (n = 33, 58% of the 57 mutations) and *FGFR3* (n = 9, 16% of the 57 mutations; [Figure 3](#fig3){ref-type="fig"}).

Mutations in the *TERT* promoter were detected in 16 of the 56 urinary cell samples from UTUC patients (29%, 95% CI, 18% to 42%; [Table 2](#table2){ref-type="table"} and [Supplementary file 11](#supp11){ref-type="supplementary-material"}). The median *TERT* MAF in the urinary cells was 2.22% and ranged from 0.59% to 46.3%. One of the 188 urinary samples from healthy individuals harbored a mutation (*TERT* g.1295250C \> T with a MAF of 0.39%). In the UTUC urinary cell samples, most of the TERT mutations (94%) were at one of two positions, TERT:g.1295228 (67%) and TERT:g.1295250 (28%), which are 66 and 88 bp upstream of the transcription start site, respectively. A third position, TERT:g.1295242, was also involved in the remaining 6% of cases.

Aneuploidy was detected in 22 of the 56 urinary cell samples from UTUC patients (39%, 95% CI, 28% to 52%, [Supplementary file 12](#supp12){ref-type="supplementary-material"} and [13](#supp13){ref-type="supplementary-material"}). The most commonly altered chromosome arms were 1q, 7q, 8q, 17 p, and 18q.

### Comparison with primary tumors {#s2-2-3}

The distribution of mutant genes in primary tumors ([Supplementary file 14](#supp14){ref-type="supplementary-material"}) was consistent with findings from some ([@bib29]; [@bib46]; [@bib96]) but not all ([@bib57]; [@bib76]), exome-wide and targeted sequencing studies of UTUCs. In the present study, *TP53* mutations were found only in high-grade UTUCs, while *FGFR3* mutations dominated in low-grade tumors (present in 5/6). Such mutational patterns have been previously reported by others ([@bib76]). However, the overall frequency of *FGFR3* mutations in our UTUC cohort (21%) was relatively low compared to values reported by [@bib57] (74%) and [@bib76] (54%), but was comparable to values reported by [@bib29] (8%) and [@bib46] (13%). We attribute this difference to the race/ethnicity profile of the cohorts under comparison, as *FGFR3* mutation levels are relatively low in UTUCs from Han Chinese patients (3--9%) compared to Western patients (36--60%), as reported by [@bib96]. Our cohort was Taiwanese and principally of Han Chinese descent, as were the [@bib29] (Taiwanese) and [@bib46] (Korean) cohorts, whereas Western patients were examined in the [@bib76] and [@bib57] studies.

Tumor samples from all 56 patients with UTUC were available for comparison and were subjected to the same three assays used to analyze the urinary cell samples. At least one mutation could be identified in the urinary cells from 39 UTUC cases. In 35 (90%) of these 39 cases, at least one of the mutations identified in the urine sample ([Supplementary file 10](#supp10){ref-type="supplementary-material"} and [11](#supp11){ref-type="supplementary-material"}) was also identified in the corresponding tumor DNA sample ([Supplementary file 14](#supp14){ref-type="supplementary-material"} and [15](#supp15){ref-type="supplementary-material"}). When all 80 mutations identified in the urinary cells were considered, 63 (79%) were identified in the corresponding tumor sample. The discrepancies between urine and tumor samples in any of the three assays might be explained by the fact that we had access to only one tumor per patient, even though more than one anatomically distinct tumor was often evident clinically ([Table 2](#table2){ref-type="table"}). In addition, DNA was extracted from only one location in each tumor; thus, intratumoral heterogeneity ([@bib52]) could have been responsible for some of the discrepancies.

The tumor data also helped to establish why 17 of the 56 urinary cell samples from UTUC patients did not contain detectable mutations. From the evaluation of the primary tumor samples, we found that only four (24%) of these 17 urine samples were from patients whose tumors did not contain any of the queried mutations ([Supplementary file 14](#supp14){ref-type="supplementary-material"} and [15](#supp15){ref-type="supplementary-material"}). Thus, we concluded that the main reason for failure of the mutation test was an insufficient number of cancer cells in the urine, which accounted for 13 (76%) of the 17 failures.

Aneuploidy was observed in 22 of the urinary cell samples ([Supplementary file 12](#supp12){ref-type="supplementary-material"}). Overall, 96% of the chromosomal gains or losses observed in the urinary cells were also observed in the primary tumors ([Supplementary file 13](#supp13){ref-type="supplementary-material"}). Conversely, aneuploidy was not observed in 34 of the urinary cell samples. Evaluation of the corresponding 56 tumors with the same assay demonstrated that all but three were aneuploid. Therefore, as with mutations, the main reason for failure of the aneuploidy assay was insufficient neoplastic DNA in the urinary cells.

### UroSEEK: biomarkers in combination {#s2-2-4}

The ten-gene multiplex assay, the *TERT* singleplex assay, and the aneuploidy assays yielded 64%, 29%, and 39% sensitivities, respectively, when used separately in the UTUC cohort ([Table 2](#table2){ref-type="table"}). Mutations in one of the other ten genes were detected in 23 samples without TERT promoter mutations ([Figure 4](#fig4){ref-type="fig"}). Conversely, three samples without detectable mutations in the multiplex assay scored positive for *TERT* promoter mutations ([Figure 4](#fig4){ref-type="fig"}). Furthermore, three of the urinary cell samples without any detectable mutations were positive for aneuploidy ([Figure 4](#fig4){ref-type="fig"}). Thus, when the three assays were used together, and a positive result in any one assay was sufficient to score a sample as positive, the sensitivity rose to 75% (95% CI 62.2% to 84.6%).

To determine the basis for the increased sensitivity afforded by the combination assays, we evaluated data from the primary tumors of the three patients whose urinary cell samples exhibited aneuploidy but did not harbor detectable mutations. We found that these three tumors did not contain any mutations in the 11 queried genes, which explained why these same assays were negative when applied to the urinary cell DNAs. These three tumors were aneuploid, thus enabling their detection through copy number variations in the urinary cell samples.

### Correlation with clinical features {#s2-2-5}

The most clinically desirable biomarkers are those associated with early stage tumor development as they enable surgical removal of lesions before widespread metastasis. In UTUC, ten-year cancer specific survival rates show that 91% of patients with stage T1 malignancies are expected to be cured by surgery, compared to only 78%, 34% and 0% of patients with stage T2, T3, or T4 tumors, respectively ([@bib49]). In our cohort, UroSEEK was equally sensitive for detecting early and late UTUCs. The test was positive in 15 (79%) of 19 patients with stage Ta/T1 tumors and 27 (73%) of 37 patients with stage T2-T4 tumors ([Table 2](#table2){ref-type="table"}). Sensitivity was comparable across gender, tumor grade, tumor location and risk factors for developing UTUC ([Table 2](#table2){ref-type="table"}), indicating that the assay was suitable for evaluation of diverse patient populations. UroSEEK performance was also comparable in UTUC cohorts with and without synchronous BC ([Table 2](#table2){ref-type="table"}).

UroSEEK was also considerably more sensitive than urine cytology in the UTUC cohort ([Figures 2](#fig2){ref-type="fig"} and [6](#fig6){ref-type="fig"}). Cytology was available in 42 cases, and of these, four (9.5%) were positive on cytology. UroSEEK detected all four of these cases. In addition, UroSEEK was positive in 5/7 cases that had an equivocal cytology diagnosis of suspicious for malignancy, and 22/31 samples that were negative on cytology.

![Bar graphs representing the performance of Cytology vs. UroSEEK in diagnosis of low- and high-grade urothelial neoplasms in the early detection and surveillance BC cohorts and the UTUC cohort.](elife-32143-fig6){#fig6}

### Aristolochic acid exposure {#s2-2-6}

The activated metabolites of AA bind covalently to the exocyclic amino groups in purine bases, with a preference for dA, leading to characteristic A \> T transversions ([@bib30]; [@bib56]). To determine whether individuals in the UTUC cohort had been exposed to AA, we quantified renal cortical DNA adducts using mass spectrometry ([@bib97]). All but two of the 56 patients had detectable aristolactam (AL)-DNA adducts ([Table 2](#table2){ref-type="table"}) with levels ranging from 0.4 to 68 dA-AL-I adducts per 10^8^ nucleotides. Moreover, the A \> T signature mutation ([@bib29]) associated with AA was highly represented in the mutational spectra of *TP53* (18/32 A \> T) and *HRAS* (2/2 A \> T) found in urinary cells ([Supplementary file 10](#supp10){ref-type="supplementary-material"}).

BC surveillance cohort {#s2-3}
----------------------

### Cohort characteristics {#s2-3-1}

Our strategy for BC surveillance was different than for early detection of BC. In these patients, a BC was surgically excised for treatment and diagnosis. Tumor tissue was thus generally available, and in most such tumors, a mutation was identified. For example, we found during the course of this study that a mutation in at least one of the 11 queried genes was present in 95.2% of BCs evaluated. We evaluated a total of 322 patients with a BC tumor containing a mutation in at least one of the 11 genes and a urine sample collected within 0--5 years after surgery. We determined whether a single urine sample taken a relatively short time following surgical excision of the BC could reveal residual disease in these 322 patients, as evidenced by later recurrence. In 187 (58%) of the 322 patients, clinically evident BC developed after a median follow-up period of 10.7 months (range 0 to 51 months). The histopathologic types and tumor stages of these patients are summarized in [Table 1b](#table1){ref-type="table"} and detailed in [Supplementary file 16](#supp16){ref-type="supplementary-material"}. The median age of the participants was 62 years (range 20 to 93), and 75% of the patients were male as expected from the demographics of BC.

### Genetic analysis {#s2-3-2}

The multiplex assay detected mutations in 52% of the urinary cell samples from patients who developed recurrent BC during the study interval (95% CI, 45% to 60%; [Supplementary file 16](#supp16){ref-type="supplementary-material"} and [Supplementary file 17](#supp17){ref-type="supplementary-material"}). The median MAF in the urinary cells with detectable mutations was 7% (6.89%). The most commonly altered genes were *FGFR3* (43% of the 134 mutations) and *TP53* (30% of the 134 mutations; [Figure 3](#fig3){ref-type="fig"}). Some cases were however considered to be false positives; 7% of the 135 patients who did not develop recurrent BC during the course of the study had a detectable mutation in their urinary cell sample (see Discussion). The mean interval between a positive multiplex assay test and the diagnosis of recurrent BC was 7 months (range 0 to 51 months).

Mutations in the *TERT* promoter were detected in 57% of the urinary cell samples from patients who developed recurrent BC during the study interval (95% CI 44% to 58%; ([Table 1b](#table1){ref-type="table"} and [Supplementary file 18](#supp18){ref-type="supplementary-material"}). The median *TERT* MAF in the urinary cells with detectable mutations was 5% (5.02%). Mutations were detected in the same three promoter positions observed in the urinary cells of the early detection cohort. The mean interval between a positive *TERT* test and the diagnosis of recurrent BC was 7 months (range 0 to 40 months). Some results were considered to be false positives; 10% (95% CI, 83% to 94%) of the 135 patients who did not develop recurrent BC during the course of the study had a detectable *TERT* promoter mutation in their urine sample.

Aneuploidy was detected in 28% (95% CI 24% to 37%) of the urinary cell samples from the patients who developed recurrent BC during the course of the study ([Table 1b](#table1){ref-type="table"} and [Supplementary file 19](#supp19){ref-type="supplementary-material"}). The most commonly altered chromosome arms were 8 p, 8q, and 9 p, as in the early detection cohort. In this assay, only 2% of the 135 patients who did not develop recurrent BC during the course of the study exhibited aneuploidy in at least one of their urinary cell samples.

### UroSEEK: biomarkers in combination {#s2-3-3}

The ten-gene multiplex assay, the *TERT* singleplex assay, and the aneuploidy assays yielded 52%, 57%, and 28% sensitivities, respectively, when used separately on the BC surveillance cohort ([Table 1b](#table1){ref-type="table"} and [Supplementary file 17](#supp17){ref-type="supplementary-material"}, [18](#supp18){ref-type="supplementary-material"} and [19](#supp19){ref-type="supplementary-material"}). Thirty-two samples without *TERT* promoter mutations were detected by mutations in one of the other ten genes ([Figure 4](#fig4){ref-type="fig"} and [Supplementary file 17](#supp17){ref-type="supplementary-material"}). Conversely, 41 samples without detectable mutations in the multiplex assay had *TERT* promoter mutations. Finally, aneuploidy was detected in three of the urinary cell samples without mutations in any of the 11 genes. Thus, the sensitivity of UroSEEK was 68% (95% CI, 59% to 73%; [Table 1b](#table1){ref-type="table"}). Twenty percent of the 135 patients in this cohort who did not develop BC during the course of the study scored positive by the UroSEEK test, yielding a specificity of 80% (95% CI, 77% to 91%). On average, UroSEEK positivity preceded the diagnosis of BC by 7 months, and in 47 cases, by \>one year ([Figure 4](#fig4){ref-type="fig"} and [Supplementary file 16](#supp16){ref-type="supplementary-material"}).

Cytology was available for 196 patients in the BC surveillance cohort ([Supplementary file 16](#supp16){ref-type="supplementary-material"}). Among the 120 patients who developed recurrent BC in this cohort, 30 (25%) were positive by cytology. Conversely, no positive cytology results were observed in patients without recurrent tumors. UroSEEK was positive in 90% of the recurrent BC patients with urines positive by cytology and in 61% of the 90 recurrent BC patients with urines negative by cytology. Thus, in combination, UroSEEK plus cytology achieved 71% sensitivity (95% CI, 61.84% to 78.77; [Figure 2](#fig2){ref-type="fig"} and [Supplementary files 17](#supp17){ref-type="supplementary-material"}, [18](#supp18){ref-type="supplementary-material"}, [19](#supp19){ref-type="supplementary-material"}). Among the 76 patients with cytology who did not develop recurrent BC during the course of the study, 18% scored as positive by either cytology or UroSEEK, which yielded a specificity of 82% (95% CI, 71% to 90%; see Discussion).

Low- vs. high-grade urothelial neoplasms (both BC cohorts) {#s2-4}
----------------------------------------------------------

The advantage of UroSEEK over cytology was particularly evident in low-grade BC (Papillary urothelial neoplasms of low malignant potential and non-invasive low-grade papillary urothelial carcinomas). Cytology was available for 49 low-grade tumors evaluated in this study (six from the early detection cohort and 43 from the Surveillance cohort). None of these low-grade tumors, however, were detected by cytology (0% sensitivity; 95% CI, 0.0% to 6.7%). In contrast, UroSEEK detected 67% (95% CI 51% to 81%) of the low-grade tumors (identical rate of 67% in both cohorts; [Supplementary file 20](#supp20){ref-type="supplementary-material"} and [Figure 6](#fig6){ref-type="fig"}). Cytology was also available for 102 high-grade tumors (in situ urothelial carcinoma, non-invasive high-grade papillary urothelial carcinoma or infiltrating high-grade urothelial carcinoma) evaluated in this study (early detection cohort, *n* = 34, and BC Surveillance cohort, *n* = 68). Cytology was positive in 45% of these patients (50% and 41% in the early detection and BC surveillance cohorts, respectively) while UroSEEK was positive in 80% (100% and 71% in the early detection and surveillance cohorts, respectively; [Supplementary file 2](#supp2){ref-type="supplementary-material"} and [16](#supp16){ref-type="supplementary-material"}).

Discussion {#s3}
==========

Cytology is a non-invasive test that is highly specific, and in expert hands nearly always indicates the presence of urothelial malignancy when positive. This specificity was verified in our study: all 51 patients in the BC early detection cohort whose urine samples were positive by cytology developed biopsy-proven BC. However, cytology is not particularly sensitive. UroSEEK adds considerably to sensitivity, as it raised the sensitivity of cytology from 43% to 95% in the BC early detection cohort, from 25% to 71% in the BC Surveillance cohort, and from 10% to 75% in the UTUC cohort. The increased sensitivity was further highlighted by the fact that UroSEEK-positive results preceded clinical diagnosis or positive cytology by months to years in the BC surveillance cohort.

The advantage of using UroSEEK in addition to cytology was particularly evident for low-grade tumors. Cytology was negative in all 49 cases in the BC early detection cohort, while 2/3 of these patients were positive with UroSEEK. Similarly, UroSEEK correctly identified 80% of low-grade UTUC while none were detected by cytology. Another example of the utility of the combination of UroSEEK plus cytology was evident in patients with an equivocal cytology reading. A relatively large number of urine samples receive such an equivocal cytologic reading, even in the hands of a sub-specialized, board-certified cytopathology expert such as employed in the current study ([@bib4]). In the BC early detection cohort, for example, 105 urine samples were scored as 'atypical', and of these cases, 19% developed recurrence while the other 81% did not. UroSEEK was positive in 95% of the atypical cases that developed BC, but only in 13% of the atypical cases that did not develop cancer. These results demonstrate that UroSEEK can be used to more confidently interpret atypical cytology results.

Although UroSEEK is more sensitive than cytology, it is less specific. In this study, we assessed specificity in several independent ways. The first, and in some ways, most straightforward, was in a collection of urine samples from healthy individuals. In these 188 individuals, only one sample was positive, yielding a specificity of 99.5% (CI 97% to 100%). Such high specificity can be considered the technical specificity of the test, but biological specificities are also important. In the BC early detection cohort, 26 of the 395 patients who did not develop BC scored positive, yielding a specificity of 93% (CI 90.50% to 96%), or a false positive rate of 6.5%. These 'false positives' detected by UroSEEK could result from several factors. First, we cannot be certain that the patients whose urinary cells harbored genetic alterations did not have cancer. The follow-up period for many of patients was only one year, and cystoscopy was not generally performed. Second, it is possible that there are clonal proliferations in the bladder epithelium that increase with age. The patients in the BC early detection cohort were on average older than the 188 healthy individuals used as controls (40 years vs. 58 years). Although this explanation is speculative, clonal proliferations that are not considered neoplastic have been described in the bone, skin, and other tissues ([@bib67]). Clonal proliferations may also be the basis for any discordance between mutations in urinary cells and in the primary tumors of the same patients. Although in the majority of cases, at least one of the mutations identified in the urine was also present in the primary tumor, this was not true in 22% of the cases in the BC early detection cohort. In these cases, UroSEEK could be detecting clonal proliferations in the bladder epithelium that did not progress to cancer, and such proliferations may be more common in patients with BC than in the general population [@bib67]Because only one biopsy from the primary tumor was available for comparison, it is also possible that intratumoral heterogeneity explains some of the discrepancies. False positives in the BC surveillance cohort could be explained in similar ways. False positives are not unique to our study; they have been observed in all other molecular assays for BC, including FDA-approved tests ([@bib15]; [@bib23]; [@bib28]). Whether the false positives in these other assays have the same biological basis is an important area for future research.

There are two factors that limit sensitivity for genetically-based biomarkers. First, a sample can only be scored as positive for the biomarker if it contains DNA from a sufficient number of neoplastic cells to be detected by the assay. Second, the tumor from which the neoplastic cells were derived must harbor the genetic alteration that is queried. Combination assays can increase sensitivity by assessing more genetic alterations, and are thereby more likely to detect at least one genetic alteration present in the tumor. However, mutations in clinical samples are often present at low allele frequencies ([Supplementary files 5](#supp5){ref-type="supplementary-material"}, [6](#supp6){ref-type="supplementary-material"}, [10](#supp10){ref-type="supplementary-material"} and [11](#supp11){ref-type="supplementary-material"}), requiring high coverage of every base queried. It would be prohibitively expensive to perform whole exome sequencing at 10,000x coverage, for example, so some compromise is needed. In our study, we evaluated carefully selected regions of 11 genes, including TERT, together with copy number analysis of 39 chromosome arms. Even if a tumor does not contain a genetic alteration in one of the 11 genes assessed, it might still be detectable by the urinary cell assay for aneuploidy. The sensitivity of aneuploidy detection however is less than that of the mutation assays. Simulations demonstrated that DNA containing a minimum of 1% neoplastic cells is required for reliable aneuploidy detection, while mutations present in as few as 0.03% of the DNA templates can be detected by the mutation assays used in our study ([@bib5]; [@bib43]; [@bib91]). Nevertheless, urinary cell samples that had relatively high fractions of neoplastic cells but did not contain a detectable mutation in the 11 queried genes should still be detectable due to their aneuploidy. In addition, some of the mutations in the 11 genes queried, such as large insertions or deletions or complex changes, might be undetectable by mutation-based assays, but such samples might still score positive in a test for aneuploidy.

For UTUC, although the approach described here has significant potential for screening purposes, we emphasize that the current study demonstrates proof-of-principle rather than clinical applicability given the small number of patients evaluated. Another caveat is that our assays cannot distinguish between UTUC and BC. We consider this a strength of the assay since the detection of BC is equally important given that patients exposed to AA are at risk for BC as well as for UTUC ([@bib65]). It has been estimated that 100 million people in China are at risk for UTUC as a result of exposure to this carcinogen ([@bib26]; [@bib33]). Non-invasive, sensitive methods to screen the large numbers of at-risk individuals for UTUC in such populations are thus clearly desirable. UroSEEK could also be used to monitor for UTUC recurrence in bladder, which occurs in 22% to 47% of cases, or in the contralateral tract affecting 2% to 6% of patients ([@bib69]) and up to 30% of AA-related UTUC patients ([@bib10]). Currently, no such screening methods are available, as illustrated in the current study where urine cytology failed to detect 90% of UTUC cases. Radiologic tests, such as MRI or CT-scans, are not well suited for screening, and the latter confers significant radiation exposure. Ureteroscopy is often definitive, but in addition to being invasive, requires highly skilled clinicians and is also ill-suited as a screening tool ([@bib21]).

Liquid biopsy has recently gained attention as a non-invasive approach to screen for cancer. Although this concept often refers to blood samples, it can be applied to other body fluids, such as urine ([@bib64]; [@bib78]; [@bib85]). Urine contains DNA from several sources, including (i) glomerular filtration of circulating free DNA ([@bib6]) released by normal and tumor cells from sites throughout the body; (ii) DNA released directly into urine by normal and tumor cells of the urinary tract; and (iii) intact normal or malignant cells of the urinary tract exfoliated into urine ([@bib5]; [@bib14]; [@bib17]; [@bib19]; [@bib27]; [@bib43]; [@bib82]; [@bib86]; [@bib89]; [@bib90]; [@bib91]). We chose the latter option for the current study to increase sensitivity and specificity.

While optimizing conditions for the current study, we compared the relative performance of mutation assays in matched plasma and urine samples obtained from 14 UTUC patients. In each case, a *TERT* or *TP53* mutation was first identified in the primary tumor. That particular mutation was subsequently queried in DNA from the urine and plasma using a singleplex assay. Mutations were detected in 93% (13/14) of the urinary cell DNA samples compared to 36% (5/14) of the plasma samples. Importantly, the plasma test failed to identify any of the six non-muscle-invasive cancers (Ta/T1), while all six (100%) were identified in the matched urinary cell DNA samples. The superior performance in urinary cells was likely due to a substantial enrichment for mutated DNA in these cells compared to plasma; the median MAF in plasma when a mutation was detectable was only 0.3% compared to 15% in the urinary cells.

Our study lays the conceptual and practical framework for a novel test that could be used in the management of patients with urothelial cancer. Large prospective trials will be required to demonstrate the ability of UroSEEK to improve the management of patients with hematuria or dysuria or patients at risk for urothelial cancer recurrence. Before carrying out large-scale trials to evaluate such clinical utility, it is informative to predict what the performance characteristics of such a test might be. As one example, consider the use of UroSEEK plus cytology in patients presenting to their physician with microscopic hematuria or dysuria, a commonly encountered situation. In large population-based studies involving over 80,000 individuals participating in health screening, the fraction of individuals with micro-hematuria ranged from 2.4% to 31.1% ([@bib13]; [@bib92]). It has been estimated that 5% of such patients actually have urothelial cancer ([@bib39]). In the current study, UroSEEK plus cytology had a sensitivity of 95% and a specificity of 93% for BC in patients with this presentation. These results extrapolate to a positive predictive value (PPV) of 66% (95% CI, 55% to 74%) and a negative predictive value (NPV) of 99.3% (95% CI, 97.3% to 99.8%). These values are well above those generally considered to be diagnostically helpful and are considerably higher than achieved in FDA-approved tests for this indication ([@bib15]; [@bib28]).

We envision that the first application of UroSEEK would be patients such as those described here in the cohorts used for early detection of BC and UTUC. Patients with hematuria who might otherwise be referred to cystoscopy would be tested by UroSEEK plus cytology. Such tests could be ordered by general practitioners and do not require consultation with a urologist. Only if a test was positive would cystoscopy be required. The sensitivities, specificities, and PPV and NPV of UroSEEK plus cytology suggest that this strategy is well within the boundaries of currently accepted medical guidelines. Optimistically, 95% of patients would be spared the discomfort and inconvenience of cystoscopy as well as its unintended consequences. Only patients who have positive UroSEEK, persistent symptoms, or hematuria would undergo cystoscopy. The savings in this approach would be considerable, as we estimate the cost of UroSEEK plus cytology to be less than 1/3 of the cost of cystoscopy.

Materials and methods {#s4}
=====================

Patients and samples {#s4-1}
--------------------

### BC early detection and BC surveillance cohorts {#s4-1-1}

Urine samples were collected prospectively from patients in four participating institutions, including Johns Hopkins Hospital, Baltimore, MD, USA; A.C. Camargo Cancer Center, Sao Paulo, Brazil; Osaka University Hospital, Osaka, Japan; and Hacettepe University Hospital, Ankara, Turkey. The study was approved by the Institutional Review Boards of Johns Hopkins Hospital and all other participating institutions. Material transfer agreements were obtained. Patients with a known history of malignancy other than BC were excluded from the study. The BC early detection cohort comprised patients who were referred to a urology clinic in one of the above hospitals because of hematuria or lower urinary tract symptoms (570 patients; [Supplementary file 2](#supp2){ref-type="supplementary-material"}). The other cohort (322 patients) represented patients with prior established diagnosis of BC who are on surveillance for disease recurrence (BC surveillance cohort). As noted in the main text, the primary tumors from these patients harbored mutations in at least one of the 11 genes assessed through the multiplex or singleplex assays. A minimum of 12 months of follow-up from the date of urine collection was required in cases with no evidence of incident (BC early detection cohort) or recurrent tumors (BC Surveillance cohort) to be included in the study. Urine samples were collected before any procedures, such as cystoscopy, were performed during patient visits. A total of 892 urine samples were analyzed and composed of two types of samples. The first was residual urinary cells after processing with standard BD SurePath liquid-based cytology protocols (Becton Dickinson and Company; Franklin Lakes, NJ, USA). To allow for standard-of-care, residual SurePath fluids were kept refrigerated for 6--8 weeks before submission for DNA purification to allow for any potential need for repeat cytology processing of the same sample. The second sample type was composed of bio-banked fresh urine samples in which 15--25 mL of voided urine samples were stored at 4˚C for up to 60 min prior to centrifugation (10 min at 500 *g*) and the pellets stored at minus 80˚C before DNA purification.

Formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples from trans-urethral resections (TURB) or cystectomies were collected in 413 of the 892 cases. When several different tumors from the same patient were available (because of recurrences), the earliest tumor tissue obtained following donation of the urine sample was used in the early detection cohort. In the Surveillance cohort, tumors obtained before the donation of the urine sample were used in 146 of the 322 patients. In the other 176 Surveillance cases, the earliest tissue obtained following the donation of the urine sample was used. A genitourinary pathologist reviewed all histologic slides to confirm the diagnosis and select a representative tumor area with as high tumor cellularity as possible for that case. Corresponding FFPE blocks were cored with a sterile 16-gauge needle. One to three cores were obtained per tumor and placed in 1.5 mL sterile tubes for DNA purification, as previously described ([@bib43]). Electronic medical records were reviewed to obtain medical history and follow up data in all patients.

### UTUC cohort {#s4-1-2}

Sequential patients with UTUC scheduled to undergo a radical unilateral nephroureterectomy at National Taiwan University Hospital, Taipei Taiwan, in 2012 - 2016 were asked to participate in the study. All patients provided informed consent using the consent form and study design reviewed and approved by the Institutional Review Boards at National Taiwan University and Stony Brook University. A total of 56 UTUC patients were enrolled in the study after excluding four patients with gross hematuria and one patient with a tumor-urine DNA mismatch by identity testing (see below).

UTUC patients provided urine samples (12 hr collection (*n* = 10); spot urines (*n* = 41); spot and 12 hr collection (*n* = 4); bladder wash (*n* = 1)) one day prior to surgery. Urinary cells were isolated by centrifugation at 581 *g* for 10 min at room temperature, washed three times in saline using the same centrifugation conditions, and stored frozen until DNA was isolated using a Qiagen kit \#937255 (Germantown, MD). DNA was purified from fresh-frozen resected samples of upper tract tumors and renal cortex by standard phenol-chloroform extraction procedures ([@bib9]; [@bib37]). One upper urinary tract tumor per patient was analyzed; for cases with tumors at multiple sites, renal pelvic tumors were preferentially selected whenever available. FFPE tumor samples were staged and graded by a urologic pathologist, and the presence of one or more UTUC was confirmed by histopathology for each enrolled individual. Pertinent clinical and demographic data were obtained by a chart review of each individual. eGFR was calculated with the MDRD equation ([@bib48]) and used to determine CKD stage ([@bib47]).

DNA adduct analysis {#s4-2}
-------------------

AL-DNA adduct (7-(deoxyadenosin-*N*^6^-yl) aristolactam I; dA-AL-I) levels in 2 µg of DNA from the normal renal cortex of UTUC patients were quantified with ultra-performance liquid chromatography--electrospray ionization/multistage mass spectrometry (UPLC-ESI/MS^n^) with a linear quadrupole ion trap mass spectrometer (LTQ Velos Pro, Thermo Fisher Scientific, San Jose, CA) as described previously ([@bib97]).

Mutation analysis {#s4-3}
-----------------

Three separate assays were used to search for abnormalities in urinary cell DNA. First, a multiplex PCR was used to detect mutations in regions of ten genes commonly mutated in urologic malignancies: *CDKN2A, ERBB2, FGFR3, HRAS, KRAS, MET, MLL, PIK3CA, TP53, and VHL* ([@bib7]; [@bib50]; [@bib54]; [@bib60]; [@bib72]; [@bib71]; [@bib70]; [@bib93]). The 57 primer pairs used for this multiplex PCR were divided in a total of three multiplex reactions, each containing non-overlapping amplicons ([Supplementary file 4](#supp4){ref-type="supplementary-material"}). These primers were used to amplify DNA in 25 µL reactions as previously described ([@bib41]), except that 15 cycles were used for the initial amplification. Second, the *TERT* promoter region was evaluated. A single amplification primer was used to amplify a 73 bp segment containing the region of the *TERT* promoter known to harbor mutations in BC and UTUC ([@bib40]; [@bib43]). The conditions used to amplify it were the same as those used in the multiplex reactions described above except that Phusion GC Buffer (Thermo-Fisher) rather than HF buffer was used, and 20 cycles were used for the initial amplification. The *TERT* promoter region was not included in the multiplex PCR because of its high GC content.

PCR products were purified with AMPure XP beads (Beckman Coulter, PA, USA) and 0.25% of the purified PCR products (multiplex) or 0.0125% of the PCR products (*TERT* singleplex) were then amplified in a second round of PCR, as described by [@bib91]. PCR products from the second round of amplification were then purified with AMPure and sequenced on an Illumina instrument. For each mutation identified, the mutant allele frequency (MAF) was determined by dividing the number of uniquely identified reads with mutations ([@bib41]) by the total number of uniquely identified reads. Each DNA sample was assessed in two independent PCRs, for both the *TERT* promoter and multiplex assays, and samples were scored as positive only if both PCRs showed the same mutation. The MAFs and number of UIDs listed in the Supplementary Tables refer to the average of the two independent assays. All coordinates are reported relative to genome reference hg19.

To evaluate the statistical significance of putative mutations, we assessed DNA from white blood cells (WBCs) of 188 unrelated healthy individuals. A variant observed in the samples from the BC or UTUC cohorts was only scored as a mutation if it was observed at a much higher MAF than observed in normal WBCs. Specifically, the classification of a sample's DNA status was based on two complementary criteria applied to each mutation: 1) the difference between the average MAF in the sample of interest and the corresponding maximum MAF observed for that same mutation in a set of controls; and 2) the Stouffer's Z-score obtained by comparing the MAF in the sample of interest to a distribution of normal controls. To calculate the Z-score, the MAF in the sample of interest was normalized based on the mutation-specific distributions of MAFs observed among all controls. Following this mutation-specific normalization, a *P*-value was obtained by comparing the MAF of each mutation in each well with a reference distribution of MAFs built from normal controls where all mutations were included. The Stouffer's Z-score was then calculated from the *P*-values of two wells, weighted by their number of UIDs. The sample was classified as positive if either the difference or the Stouffer's Z-score of its mutations was above the thresholds determined from the normal WBCs. The threshold for the difference parameter was defined by the highest MAF observed in any normal WBCs. The threshold for the Stouffer\'s Z-score was chosen to allow one false positive among the 188 normal urine samples studied (see below).

Analysis of aneuploidy {#s4-4}
----------------------

Aneuploidy was assessed with FastSeqS, which uses a single primer pair to amplify \~38,000 loci scattered throughout the genome ([@bib42]). After massively parallel sequencing, gains or losses of each of the 39 chromosome arms covered by the assay were determined using a bespoke statistical learning method described in [@bib16]. A support vector machine (SVM) was used to discriminate between aneuploid and euploid samples. The SVM was trained using 3150 low neoplastic cell fraction synthetic aneuploid samples and 677 euploid peripheral WBC samples. Samples were scored as positive when the genome-wide aneuploidy score was \>0.7, and there was at least one gain or loss of a chromosome arm.

Identity checks {#s4-5}
---------------

A multiplex reaction containing 26 primers detecting 31 common SNPs on chromosomes 10 and 20 was performed using the amplification conditions described above for the multiplex PCR. The 26 primers used for this identity evaluation are listed in [Supplementary file 21](#supp21){ref-type="supplementary-material"}.

Normal control samples {#s4-6}
----------------------

Urine samples from 188 healthy volunteers (19--60 years; mean age 26 years) were obtained and processed identically to the bio-banked fresh urine samples as described above. Urinary cell DNA from these 188 samples was used to assess the specificity of the UroSEEK test. WBC DNA from 94 normal individuals was used to evaluate the technical specificity of the PCR analysis.

Statistical analysis {#s4-7}
--------------------

Performance characteristics of urine cytology, UroSEEK and its three components were calculated using MedCalc statistical software, online version (<https://www.medcalc.org/calc/diagnostic_test.php>). Confidence intervals (95%) were determined with an online GraphPad Software Inc. statistical calculator (<https://www.graphpad.com/quickcalcs/confInterval1/>) using the modified Wald method.
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Decision letter
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Non-invasive detection of bladder cancer through the analysis of driver gene mutations and aneuploidy\" for consideration by *eLife*. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by Ross Levine as Reviewing Editor (and one of the reviewers) and Charles Sawyers as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

In summary, in the two manuscripts the authors develop a non-invasive molecular test called UroSEEK to analyze DNA from urinary CELLS shed into the urine. UroSEEK combines three assessments including mutations from exons in 11 genes, TERT mutations, and aneuploidy. UroSEEK has the potential to augment the sensitivity of routine cytology for the detection of cancer in patients with bladder cancer and upper tract urothelial carcinomas. For the bladder study, they looked at two cohorts, one with hematuria and the second with previous bladder cancer history at risk for new bladder cancers. For the urothelial study, this included 56 subjects with urothelial cancer. For each cohort, they used the same 188 control urine specimens from healthy subjects as negative controls. The main conclusion from these studies is the same -- urinary cell mutation testing has potential to detect urothelial and bladder cancers. As such, we think it is best to combine these papers into a single report, which would be of broad interest to the field.

Essential Revisions:

1\) There is significant overlap between these two manuscripts, and reading these separately does not add value to either one\'s conclusion, especially in the same journal issue of *eLife*. The clinical and diagnostics audience for urothelial and bladder cancer is the same. While the clinical cohorts are different, the genes, methods, controls, and disease (based on their common mutation assessment with URoSEEK) are identical. The written methods are identical. The message is the same -- urinary cell mutation testing has potential to detect urothelial and bladder cancers.

2\) The issue of how this approach compares to cystoscopy is a major one and is not thoughtfully discussed. If both tests are similar in cost, and cystoscopy is more invasive but definitive, will patients and payers want to use an equally costly non-invasive test vs the more definitive test? How would the authors propose to use this as part of the diagnostic workup and can the impact be modeled in terms of costs, \# procedures, etc.? Would add value.

3\) The lack of specificity, particularly with respect to positive genetic data in 1) patients without cancer and 2) in patients who previously had cancer and did not recur, is a substantive issue. Can this be improved? Are there ways to deal with this issue in terms of proposing a diagnostic approach? On this note, the methods/assay used have not been thoroughly vetted for sensitivity, specificity, limits of detection and reproducibility for a clinical assay, typically done with serial dilutions and replicates. The authors indicate that one reason for false negatives was due to discordant mutations on the gene panel and the tumor. Another reason could be the assay\'s limits of detection. While this has not been completed, nonetheless, it does not significantly diminish the conclusion from these studies that urinary cell mutation testing could augment cytology.

4\) Have the authors modeled whether including more, or less than 11 genes + TERT/aneuploidy, would impact performance of the test? Are there ways to improve the design to improve performance?

5\) Why did the authors separate these assays especially that the three assays that make up UroSEEK can be combined in one NGS platform (examples include assays developed by Foundation Medicine, MSK-IMPACT, Oncomine panel, etc.) that can provide more comprehensive genetic analysis on many more genes including mutations and copy number alterations. Some of the currently available NSG platforms can also utilize cfDNA.

The list of genes in the assay, while includes some of the very commonly mutated genes in bladder cancer, it leaves out other genes that are both relevant and common including for example ARID1A, KDM6A, CDKN1A, STAG2, MLL2/MLL3, etc. Including such genes would very likely improve the assay.

10.7554/eLife.32143.034

Author response

> Essential Revisions:

*1) There is significant overlap between these two manuscripts, and reading these separately does not add value to either one\'s conclusion, especially in the same journal issue of* eLife*. The clinical and diagnostics audience for urothelial and bladder cancer is the same. While the clinical cohorts are different, the genes, methods, controls, and disease (based on their common mutation assessment with URoSEEK) are identical. The written methods are identical. The message is the same -- urinary cell mutation testing has potential to detect urothelial and bladder cancers.*

The two manuscripts have been integrated into a single paper as requested.

> 2\) The issue of how this approach compares to cystoscopy is a major one and is not thoughtfully discussed. If both tests are similar in cost, and cystoscopy is more invasive but definitive, will patients and payers want to use an equally costly non-invasive test vs the more definitive test? How would the authors propose to use this as part of the diagnostic workup and can the impact be modeled in terms of costs, \# procedures, etc.? Would add value.

This is an important point, and we appreciate the reviewer\'s bringing it up. Cystoscopy is definitely definitive but is invasive and always associated with pain and inconvenience and occasionally associated with side effects such as infection, bleeding, urethral stenosis, etc. The procedure also requires skilled professionals to perform it. As the great majority of patients in some screening settings (e.g., hematuria) do not have cancer, these issues are precisely those that inspired our study. It is widely agreed that a non-invasive test that could be used to screen patients in such settings could minimize the need for cystoscopy and its unintended consequences.

The cost of cystoscopy is up to \$3200, not including the cost of the pathology of biopsies. The cost of ureteroscopy is similar. We envision that the cost of UroSEEK plus cytology would be \<\$750 when implemented in a commercial setting, using savings afforded by economy-of scale. We anticipate that \>90% of patients with hematuria who would otherwise undergo cystoscopy could be spared this procedure on the basis of a negative UroSEEK test The entire cost savings, integrated over all patients, would therefore be considerable: for every 100 patients evaluated, up to \$200,000 would be saved (assuming UroSEEK plus cytology in all patients plus cystoscopy in 5% of the patients who test positive with UroSEEK). This translates to many millions of dollars in the U.S. annually, and does not include the cost of follow-ups for the side effects of cystoscopy when performed. These issues are now briefly discussed at the end of the revised Discussion.

> 3\) The lack of specificity, particularly with respect to positive genetic data in 1) patients without cancer and 2) in patients who previously had cancer and did not recur, is a substantive issue. Can this be improved? Are there ways to deal with this issue in terms of proposing a diagnostic approach?

We agree with the reviewers that specificity is important, but there are two kinds of specificity. Technical specificity can be assessed from the evaluation of the test in DNA from totally normal individuals, such as DNA from normal WBCs. The technical specificity of UroSEEK is very high, over 99%, as reported in the manuscript. Biological specificity is different and reflects the cohorts studied. In urines from normal individuals (without any hematuria, for example), the specificity is as high as in as in normal WBCs (\>99%). As noted in the manuscript, though, this specificity is not as high in other cohorts. In the Discussion, this issue is discussed at length. For example, the 6.5% false positives in BC early detection cohort could be related to a lead time ahead of "clinical" detection. The follow-up period for many of patients was only one year, and cystoscopy was not performed in every patient as per current standards. The same issue could lead to apparently false positive results in the surveillance cohort, in which patients are at much higher risk for cancer than in the early detection cohorts. We will attempt to address such possibilities in future prospective studies that we are now planning where a longer follow up (e.g. 3 years minimum) should be helpful. False positives are not unique to our study; they have been observed in all other molecular assays for bladder cancer, including those that are FDA- approved. Even assuming that none of the false positives are due to as yet undetected cancers, the positive predictive values and negative predictive values in the early detection cohorts is considerably above what has been required for FDA-approval of diagnostic tests in general.

> On this note, the methods/assay used have not been thoroughly vetted for sensitivity, specificity, limits of detection and reproducibility for a clinical assay, typically done with serial dilutions and replicates. The authors indicate that one reason for false negatives was due to discordant mutations on the gene panel and the tumor. Another reason could be the assay\'s limits of detection. While this has not been completed, nonetheless, it does not significantly diminish the conclusion from these studies that urinary cell mutation testing could augment cytology.

We appreciate the reviewers' view that such detailed vetting is not critical for the conclusions made in this manuscript. But we would like to highlight several pieces of data that address this point. The reproducibility of the test has been exhaustively examined, because tests were scored positive *if and only if* an independent assay of DNA from the same urine sample was also positive. Moreover, the coefficients of variation of the duplicates were high, as noted in the table below (which can easily be recalculated by readers using the data recorded in the Supplementary files, wherein the results of each replicate are specified). We note that the CVs are relatively low even when the MAFs are low, meaning that there are only a few molecules present, helping to establish technical sensitivity (limit of sensitivity).

UroSEEK requires no complex molecular biological manipulations of DNA; it simply uses PCR of DNA purified from the urine. Thus, many of the issues that are faced by other next generation sequencing technologies, such as those involved in end-polishing of DNA, ligations, and captures, are avoided. The reproducibility and sensitivity of SafeSeqS, which is the basis for UroSEEK, has been previously documented in the original paper (Kinde et al., Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A, 108(23), 9530-9535).

Finally, we are in the process of licensing UroSEEK to a small start-up company that was founded by some of the senior authors of this study. As part of their due diligence and preparation for an upcoming clinical trial of UroSEEK based on the results reported in our manuscript, they have prepared a Clinical Laboratory Improvement Amendment (CLIA) report. Though the report cannot be made public, it provides additional evidence of the reproducibility of UroSEEK in a completely different laboratory.

CV (SD/Mean\*100)Mutation Group (classified by MAF)All\>10%\>5%\>2%\>1%\>0.5%\<0.5%All16.558.399.5511.7013.1015.0235.53BC Surveillance18.008.729.6812.7013.4814.9532.23BC early detection15.868.6710.0911.6013.2615.1727.21UTUC cohort15.185.976.388.8211.1614.586.77

> 4\) Have the authors modeled whether including more, or less than 11 genes + TERT/aneuploidy, would impact performance of the test? Are there ways to improve the design to improve performance?

This is an excellent question. The genes chosen for the analysis were based on a comprehensive evaluation of the literature on bladder cancer (insufficient data existed for UTUC, but prior publications indicate that the genetic alterations in upper and lower urinary tract cancers are similar). We modeled how additional genes would impact the assay by looking at the inclusion of other amplicons from the top 20 genes contributing to bladder cancer development listed in the COSMIC database. As shown in the figure in Supplementary file 1, the 59 amplicons chosen are above the asymptote in this graph, meaning that more amplicons would not substantially to sensitivity. More amplicons would however, increase the cost and indirectly decrease the sensitivity by decreasing specificity. The reason for this decrease in sensitivity is that the probabilistic models used to interpret rare mutations are rooted in multiple hypothesis testing; the more amplicons studied, the greater the possibility for false positives. The Bonferroni correction is an early example of an approach for dealing with this issue. The new figure illustrates that our choice of amplicons was reasonable. Moreover, the point in the graph (at 59 amplicons) shows that the expected sensitivity was actually realized in the primary bladder cancers that we studied, and was not just theoretical based on expectations from the COSMIC database.

We have included this graph as a new figure in Supplementary file 1 to illustrate this important concept.

> 5\) Why did the authors separate these assays especially that the three assays that make up UroSEEK can be combined in one NGS platform (examples include assays developed by Foundation Medicine, MSK-IMPACT, Oncomine panel, etc.) that can provide more comprehensive genetic analysis on many more genes including mutations and copy number alterations. Some of the currently available NSG platforms can also utilize cfDNA.

As mentioned in the manuscript, *TERT* promoter region is very CG rich and difficult to amplify. This forced us to exclude it from the rest of the panel and sequence it alone. The Aneuploidy test requires a completely different amplification strategy due the large number of total regions that are assessed (\~30,000).

We are keenly aware of the other tests cited by the reviewers because they are largely based on the strategy we described earlier, using endogenous rather than exogenous molecular barcodes (Kinde reference above). Though it is beyond the scope of our article to discuss their strengths and weaknesses, we note that these other tests are designed to detect relatively high fractions of mutant DNA, much higher than those we observed in many urine samples, at a much larger number of genomic positions. Additionally, they are far more expensive than UroSEEK and not well-suited for screening purposes. UroSEEK is unique so far in that it can assess a relatively small (but adequate) number of amplicons at very high depth and sensitivity at minimal cost.

> The list of genes in the assay, while includes some of the very commonly mutated genes in bladder cancer, it leaves out other genes that are both relevant and common including for example ARID1A, KDM6A, CDKN1A, STAG2, MLL2/MLL3, etc. Including such genes would very likely improve the assay.

We again thank the reviewers for this suggestion, but note that the inclusion of these other amplicons would not substantially increase the sensitivity of the assay, as documented by the figure in Supplementary file 1 (and now included in the revised manuscript). We also note that cancers that do not harbor mutations in the 59 individual amplicons evaluated can still be aneuploid and can therefore be detected with the third component of UroSEEK, which detects aneuploidy.

[^1]: These authors contributed equally to this work.
